{"id":"NCT02368210","sponsor":"Therapeutics, Inc.","briefTitle":"A Comparison of 122-0551 Foam Versus Vehicle Foam in Subjects With Plaque Psoriasis (Study 306)","officialTitle":"A Multicenter, Randomized, Double-Blind, Parallel Group Comparison of 122-0551 Foam Versus Vehicle Foam in Subjects With Plaque Psoriasis (Study 306)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-01","primaryCompletion":"2015-06","completion":"2017-02","firstPosted":"2015-02-23","resultsPosted":"2018-11-26","lastUpdate":"2018-11-26"},"enrollment":151,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Plaque Psoriasis"],"interventions":[{"type":"DRUG","name":"122-0551 Foam","otherNames":[]},{"type":"DRUG","name":"Vehicle Foam","otherNames":[]}],"arms":[{"label":"122-0551 Foam","type":"EXPERIMENTAL"},{"label":"Vehicle Foam","type":"PLACEBO_COMPARATOR"}],"summary":"This Phase 3 study (Study 306) has been designed to determine and compare the efficacy and safety of 122-0551 Foam and Vehicle Foam applied twice daily for two weeks in subjects with plaque psoriasis.","primaryOutcome":{"measure":"Percentage of Subjects Rated a \"Treatment Success\" Based on the Investigator's Global Assessment (IGA)","timeFrame":"Day 15","effectByArm":[{"arm":"122-0551 Foam","deltaMin":25.3,"sd":null},{"arm":"Vehicle Foam","deltaMin":3.9,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":7},"locations":{"siteCount":8,"countries":["United States"]},"refs":{"pmids":["31424709"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":75},"commonTop":["Abdominal pain","Application site pain","Application site pruritus","Cellulitis","Hordeolum"]}}